Lung Cancer & COPD | Dr. Bai Chong (Pulmonology) | CMCS Shanghai

About Dr. Bai Chong

Dr. Bai Chong is Chief of Pulmonary and Critical Care Medicine at Changhai Hospital, Naval Medical University (Shanghai) — one of China's foremost academic centres for interventional pulmonology, lung cancer diagnosis and treatment, and complex airway disease management. He is a nationally recognised leader in interventional bronchoscopy, with particular expertise in electromagnetic navigation bronchoscopy (ENB), rigid bronchoscopy, endobronchial ultrasound (EBUS), and bronchoscopic thermal ablation for peripheral lung tumours. Dr. Bai pioneered the integration of rigid bronchoscopy as the foundational airway platform for complex interventional procedures at Changhai Hospital — providing a stable ventilation channel, eliminating airway collapse risk in high-risk patients, and creating a secure corridor for haemorrhage control during ablation. His centre is a national reference site for the combination of ENB-guided biopsy with rapid on-site evaluation (ROSE) and same-session microwave ablation — the diagnostic-therapeutic integration strategy that eliminates the need for a second anaesthetic in inoperable patients. Dr. Bai has published extensively in Chest, Journal of Thoracic Oncology, and Respiration, and serves on the expert committees of the Chinese Society of Respiratory Medicine.

Case Overview

Mr. George Whitfield, a 72-year-old British retired military officer, presented with an incidentally identified right lower lobe pulmonary nodule against a background of ten years of severe COPD and prior coronary artery disease with PCI. Pulmonary function testing confirmed critically impaired ventilatory reserve: FEV1 0.9 L (35% predicted), FEV1/FVC 45%, DLCO 40% — placing him at prohibitively high risk for any surgical resection. CT demonstrated a 1.8 x 1.5 cm mixed ground-glass opacity (mGGO) in the right lower lobe posterior segment with 30% solid component, lobulation, and spiculation. PET-CT confirmed SUVmax 4.5 with no mediastinal or distant metastatic activity. Clinical staging: T1cN0M0, Stage IA2. Dr. Bai Chong designed a same-session diagnostic-therapeutic strategy under rigid bronchoscopy: ENB navigation to the peripheral nodule, biopsy with ROSE to confirm malignancy, and immediate microwave ablation (MWA) through the same bronchoscopic channel. Intraoperative C-arm CT confirmed ablation zone coverage exceeding 1 cm beyond the tumour margin. At one-year follow-up, the ablation site had evolved to a stable fibrotic scar with no local recurrence and stable FEV1.

Patient Background

• Name / Nationality: Mr. George Whitfield (pseudonym) — British
• Age / Sex: 72-year-old male
• Occupation: Retired military officer — 40 pack-year smoking history (ceased 5 years prior); long-term dust exposure
• Chief Complaint: Cough and exertional dyspnoea for 10 years; right lung nodule identified incidentally on surveillance CT
• Comorbidities: Severe COPD (GOLD Group D); coronary artery disease (prior PCI); hypertension
• Pulmonary Function: FEV1 0.9 L (35% predicted); FEV1/FVC 45%; DLCO 40% — surgical resection contraindicated
• Surgical Risk: Predicted post-lobectomy FEV1 below 0.6 L — incompatible with independent ventilation; wedge resection also high perioperative mortality risk

Imaging and Diagnosis

Chest CT (High-Resolution)

• Location: Right lower lobe posterior segment (S6) — peripheral, subpleural, within 5 mm of visceral pleura
• Morphology: mGGO 1.8 x 1.5 cm; solid component 30%; lobulated margins; spiculation — high malignancy risk
• Airways: Severe bilateral emphysema; no endobronchial lesion

PET-CT

• Nodule: SUVmax 4.5 — metabolically active, consistent with malignancy
• Mediastinum and distant sites: No abnormal FDG uptake — N0M0 confirmed

Clinical Staging and Diagnosis

• Stage: T1cN0M0 — AJCC Stage IA2
• Surgical status: Inoperable — critically impaired pulmonary reserve
• Treatment plan: Same-session ENB-guided biopsy + ROSE + microwave ablation under rigid bronchoscopy

Clinical Decision Making

Three compounding challenges defined this case: a peripheral nodule inaccessible to conventional bronchoscopy and too high-risk for CT-guided percutaneous biopsy (pneumothorax in a patient with FEV1 35% predicted would be immediately life-threatening); surgical resection contraindicated by critically impaired pulmonary reserve; and the need to achieve surgical-equivalent local tumour control without removing any lung parenchyma. SBRT was considered but assessed as suboptimal given pleural proximity and radiation pneumonitis risk in severely compromised lung.

Dr. Bai Chong's procedural strategy: This patient cannot have surgery. His FEV1 is 35% predicted — if we take a lobe, we take his ability to breathe independently. But he has a Stage IA2 adenocarcinoma that is curable if we treat it correctly. ENB gets us to the nodule without a needle through the chest wall — no pneumothorax risk. ROSE tells us immediately whether the biopsy is diagnostic. And if it is, we do not wake him up and bring him back for a second procedure. We ablate it in the same sitting. One anaesthetic. One procedure. Diagnosis and treatment complete. The rigid bronchoscope is our safety net throughout: if he bleeds, we control it through the rigid channel. For a patient with GOLD Group D COPD, the rigid bronchoscope is not optional. It is the foundation of the entire procedure.

Procedural Details

Phase 1 — Rigid Bronchoscopy Platform

Anaesthesia: Total intravenous anaesthesia (TIVA) — avoiding volatile agents that may trigger bronchospasm in severe COPD
Airway: Rigid bronchoscope inserted under direct laryngoscopy — stable secured airway with continuous high-frequency jet ventilation (HFJV) throughout, maintaining oxygenation while the working channel remained available for ENB catheter and ablation needle

Dr. Bai's procedural note: The rigid bronchoscope is the airway — not an instrument passed through the airway. It provides ventilation, access, and the emergency channel we need if anything goes wrong. We do not perform thermal ablation in high-risk patients without it.

Phase 2 — ENB Navigation, Biopsy, and ROSE

Navigation: SuperDimension ENB platform with pre-procedural virtual bronchoscopy reconstruction from CT dataset — generating a 3D airway map and planned pathway to the right lower lobe S6 nodule. Electromagnetic positioning board placed beneath the patient; registration performed using anatomical landmarks.

The extended working channel (EWC) catheter was advanced through the rigid bronchoscope under real-time electromagnetic navigation guidance. Navigation display confirmed Target Reached; fluoroscopic confirmation in two planes verified catheter position at the nodule.

Biopsy: Bronchial brush and biopsy forceps passed through the EWC; fluoroscopy confirmed sampling from within the nodule boundary.
ROSE result (within 5 minutes): Atypical glandular cells consistent with adenocarcinoma — malignancy confirmed. Immediate transition to ablation phase.

Dr. Bai's procedural note: ROSE is the decision point. If positive, we ablate immediately — same position, same channel, same anaesthetic. In this case, the cytopathologist confirmed adenocarcinoma within five minutes. We did not hesitate. That is the closed-loop diagnostic-therapeutic strategy that defines our approach to inoperable peripheral lung cancer.

Phase 3 — Microwave Ablation (MWA)

Needle placement: Microwave ablation needle advanced through the rigid bronchoscope working channel and locked EWC into the nodule centre — confirmed by fluoroscopy and C-arm CT
Parameters: 60 W, 10 minutes — targeting ablation zone temperature above 60°C with ≥1 cm margin beyond tumour boundary
Pleural protection: Normal saline instilled to create artificial hydrothorax — interposing a fluid thermal buffer between the ablation zone and the visceral pleura, preventing pneumothorax (hydrodissection technique)
Margin confirmation: C-arm CT cone-beam scan confirmed ablation zone (ground-glass opacity) extending more than 1 cm beyond tumour margin in all directions

Dr. Bai's procedural note: Microwave ablation in the lung is not the same as in the liver. Air is a thermal insulator — heat distribution is unpredictable near alveoli and large vessels. The heat sink effect from pulmonary vessels can create cold spots where tumour cells survive. We confirm the margin with C-arm CT before withdrawing the needle. We do not guess the ablation margin. We measure it.

Phase 4 — Haemostasis and Airway Assessment

Small endobronchial bleeding identified at biopsy site following needle withdrawal. Cryoprobe applied through the rigid bronchoscope working channel — haemostasis achieved within 60 seconds via cryoadhesion. Full right bronchial tree inspection confirmed no active bleeding, no bronchial wall perforation, no bronchopleural fistula.

Post-operative Management and Follow-up

Immediate Post-procedural Care

• Monitoring: RICU for 24 hours — arterial blood gas, continuous pulse oximetry, chest radiography at 2 and 6 hours
• Respiratory support: BiPAP non-invasive ventilation for 4 hours post-extubation
• Bronchodilator therapy: Nebulised SABA + ipratropium; systemic corticosteroids for 48 hours — preventing COPD acute exacerbation
• Pneumothorax: None — hydrodissection technique effective

Imaging Follow-up

• 1-week CT: High-density consolidation at ablation zone; no pneumothorax; small reactive pleural effusion resolving
• 3-month CT: Ablation zone reducing; original nodule replaced by evolving fibrotic scar; no contrast enhancement — complete ablation response
• 1-year CT: Stable fibrotic scar; no local recurrence; no regional or distant metastasis

Pulmonary Function at 1 Year

• FEV1: 0.88 L — no significant decline from pre-procedural baseline (0.9 L); lung parenchyma preservation confirmed
• Exercise tolerance: Stable; 6-minute walk distance unchanged
• COPD management: Optimised triple inhaler therapy (LABA + LAMA + ICS); pulmonary rehabilitation maintained

Extended Case: ENB Cryobiopsy and EBUS-TBNA for Synchronous Peripheral Nodule and Mediastinal Lymphadenopathy

Dr. Bai Chong's expertise extends to the most diagnostically complex scenario in thoracic oncology: synchronous peripheral nodule and mediastinal lymphadenopathy requiring simultaneous peripheral and central staging in a single bronchoscopic session. A 65-year-old American woman presented with a 2.2 cm right upper lobe peripheral nodule and enlarged right paratracheal lymph nodes (station 4R). Under rigid bronchoscopy, Dr. Bai performed ENB-guided cryobiopsy of the peripheral nodule — obtaining a core tissue sample sufficient for full molecular profiling including EGFR, ALK, ROS1, PD-L1, and next-generation sequencing — followed immediately by EBUS-TBNA of station 4R. ROSE confirmed adenocarcinoma at the nodule and reactive lymphoid tissue at 4R — establishing Stage IA3 disease in a single session. EGFR exon 19 deletion was identified; the patient commenced osimertinib. At 12-month follow-up, CT demonstrated 40% tumour volume reduction. This case exemplifies the principle that the bronchoscopic platform — combining ENB, EBUS, cryobiopsy, and ROSE — can replace multiple separate diagnostic procedures with a single comprehensive staging session.

Expert Commentary — Dr. Bai Chong

1. The Rigid Bronchoscope: The Foundation of Safe Interventional Pulmonology

Flexible bronchoscopy has transformed pulmonary medicine — but it has critical limitations in high-risk patients. In a patient with FEV1 35% predicted, passing a flexible bronchoscope through the vocal cords narrows the effective airway diameter, increases resistance, and risks dynamic hyperinflation and respiratory failure. The rigid bronchoscope eliminates these risks. It is the airway — not an instrument passed through the airway. It provides continuous controlled ventilation, a working channel large enough for an ablation needle or cryoprobe, and the emergency corridor for managing haemorrhage or tension pneumothorax. For complex interventional procedures in high-risk patients, the rigid bronchoscope is not an option. It is the standard of care.

2. The Diagnostic-Therapeutic Closed Loop: ENB, ROSE, and Same-Session Ablation

The conventional pathway for a peripheral lung nodule in an inoperable patient involves multiple separate procedures: CT-guided biopsy with pneumothorax risk, a waiting period for pathology, multidisciplinary tumour board discussion, and then a separate ablation or radiotherapy session — often weeks later. Our same-session ENB-guided biopsy with ROSE and immediate microwave ablation collapses this pathway into a single procedure. ROSE gives us the pathological answer within five minutes. If the answer is malignancy, we ablate immediately — same position, same channel, same anaesthetic. The diagnostic yield of ENB with ROSE in our centre exceeds 90% for nodules above 1.5 cm. For inoperable patients, this closed loop is not a convenience. It is the difference between timely curative treatment and a prolonged diagnostic odyssey.

3. Thermal Ablation in the Lung: Mastering the Heat Sink Effect

Microwave ablation in the lung is technically more demanding than in the liver or kidney. The lung is predominantly air — a thermal insulator that creates unpredictable heat distribution. Pulmonary vessels adjacent to the ablation zone act as heat sinks, conducting thermal energy away from the target and creating cold spots where tumour cells may survive. We compensate through power titration, multi-point overlapping ablation for larger nodules, and intraoperative C-arm CT confirmation of the ablation margin before needle withdrawal. For nodules adjacent to the visceral pleura, the hydrodissection technique interposes a saline thermal buffer between the ablation zone and the pleural surface, preventing pneumothorax and pleural injury. Mastering these techniques is the difference between complete tumour necrosis and a margin failure.

4. Lung Function Preservation as the Primary Outcome in COPD-Associated Lung Cancer

For patients with severe COPD and lung cancer, the oncological and pulmonary functional outcomes are inseparable. A patient who achieves local tumour control but loses 30% of remaining FEV1 to surgical resection has not been cured — they have been exchanged from one life-threatening condition to another. Microwave ablation destroys the tumour without removing lung parenchyma. In our series of COPD patients treated with bronchoscopic ablation, mean FEV1 decline at one year is less than 3% of baseline — compared with 15–25% following wedge resection and 30–40% following lobectomy. For patients with FEV1 below 50% predicted, bronchoscopic ablation is not a compromise. It is the correct treatment. Preserving lung function is preserving life.

How CMCS Shanghai Coordinated This Case

China Medical Concierge Shanghai (CMCS) supported Mr. Whitfield's care pathway from initial overseas inquiry through one-year post-procedural surveillance. Our coordination included:

• Pre-arrival review of chest CT, PET-CT, pulmonary function tests, cardiac catheterisation records, and COPD management history; specialist referral to Dr. Bai Chong's interventional pulmonology team at Changhai Hospital, Naval Medical University
• Arrangement of comprehensive pre-procedural assessment: repeat high-resolution CT with 3D nodule reconstruction for ENB pathway planning, updated pulmonary function testing, arterial blood gas analysis, echocardiography, and anaesthesia risk assessment — ENB navigation pathway planned prior to the patient's arrival in Shanghai
• Bilingual interpretation during the pre-procedural consultation — including explanation of the Stage IA2 diagnosis, surgical contraindication rationale, ENB navigation technology, ROSE same-session biopsy-to-ablation strategy, rigid bronchoscopy safety platform, microwave ablation mechanism and margin confirmation protocol, and hydrodissection pleural protection technique
• Facilitation of informed procedural consent — ensuring Mr. Whitfield fully understood the diagnostic-therapeutic integration strategy, pneumothorax prevention protocol, RICU monitoring, and one-year imaging surveillance schedule
• Procedural admission logistics: interventional bronchoscopy suite scheduling, RICU bed reservation, anaesthesia pre-assessment, and accommodation support for accompanying family
• On-site medical interpretation throughout hospitalisation — ROSE result communication, C-arm CT ablation margin explanation, BiPAP ventilation guidance, and discharge planning
• Post-procedural COPD management coordination: optimised triple inhaler therapy guidance; pulmonary rehabilitation referral in Shanghai; written rehabilitation and inhaler protocol translated into English for continuation with Mr. Whitfield's respiratory physician in the UK
• Imaging surveillance coordination: 1-week, 3-month, and 1-year CT scheduling; results translation and communication to the UK respiratory physician and oncologist; ablation response assessment at each time point
• One-year follow-up: pulmonary function testing, CT surveillance, and oncological assessment; confirmation of local tumour control and stable FEV1; long-term surveillance schedule established per NCCN and ESMO guidelines

For international patients facing peripheral lung cancer who cannot tolerate surgical resection — particularly those with severe COPD, prior cardiac disease, or critically impaired pulmonary reserve — the combination of electromagnetic navigation bronchoscopy, same-session ROSE-confirmed biopsy and microwave ablation, rigid bronchoscopy safety platform, and lung-function-preserving philosophy at Changhai Hospital represents a standard of interventional pulmonology genuinely at the international frontier. CMCS exists to connect patients with that expertise: ensuring every non-surgical treatment option is evaluated, every procedural risk is explained in their language, and every step from ENB pathway planning to long-term ablation surveillance is coordinated across borders with precision and care.

This case report is de-identified and published for educational purposes. All clinical details have been anonymized in accordance with patient privacy standards. CMCS Shanghai is a medical concierge service and does not provide direct medical care.